Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
LRRK2
More Information »Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. Mutations in LRRK2 are commonly associated with late-onset Parkinson's disease (PD).
LRRK2 Products
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 4534 |
CZC 54252 hydrochloride
|
| Potent LRRK2 inhibitor; neuroprotective | |
| 4629 |
GSK2578215A
|
| Potent, selective LRRK2 inhibitor; brain penetrant | |
| 4273 | LRRK2-IN-1 |
| Potent and selective LRRK2 inhibitor | |
Related Categories
Quick Order
Find multiple products by catalog number
Kinases Product Listing
Highlights over 350 products for kinase research. Request a copy or view PDF today.
Kinase Inhibitor Toolbox
80 Kinase inhibitors
pre-dissolved in DMSO
Some of the most potent
kinase inhibitors all on one plate
Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.